PortalPublikationenIgE immunotherapy: a novel concept with promise for the trea...

IgE immunotherapy: a novel concept with promise for the treatment of cancer

Standard

IgE immunotherapy: a novel concept with promise for the treatment of cancer. / Josephs, Debra H; Spicer, James F; Karagiannis, Panagiotis; Gould, Hannah J; Karagiannis, Sophia N.

in: MABS-AUSTIN, Jahrgang 6, Nr. 1, 16.01.2014, S. 54-72.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Josephs, DH, Spicer, JF, Karagiannis, P, Gould, HJ & Karagiannis, SN 2014, 'IgE immunotherapy: a novel concept with promise for the treatment of cancer', MABS-AUSTIN, Jg. 6, Nr. 1, S. 54-72. https://doi.org/10.4161/mabs.27029

APA

Josephs, D. H., Spicer, J. F., Karagiannis, P., Gould, H. J., & Karagiannis, S. N. (2014). IgE immunotherapy: a novel concept with promise for the treatment of cancer. MABS-AUSTIN, 6(1), 54-72. https://doi.org/10.4161/mabs.27029

Vancouver

Josephs DH, Spicer JF, Karagiannis P, Gould HJ, Karagiannis SN. IgE immunotherapy: a novel concept with promise for the treatment of cancer. MABS-AUSTIN. 2014 Jan 16;6(1):54-72. https://doi.org/10.4161/mabs.27029

Bibtex

@article{66d25c2388504e1cac0c9734418af629,
title = "IgE immunotherapy: a novel concept with promise for the treatment of cancer",
abstract = "The importance of antibodies in activating immune responses against tumors is now better appreciated with the emergence of checkpoint blockade antibodies and with engineered antibody Fc domains featuring enhanced capacity to focus potent effector cells against cancer cells. Antibodies designed with Fc regions of the IgE class can confer natural, potent, long-lived immune surveillance in tissues through tenacious engagement of high-affinity cognate Fc receptors on distinct, often tumor-resident immune effector cells, and through ability to activate these cells under tumor-induced Th2-biased conditions. Here, we review the properties that make IgE a contributor to the allergic response and a critical player in the protection against parasites, which also support IgE as a novel anti-cancer modality. We discuss IgE-based active and passive immunotherapeutic approaches in disparate in vitro and in vivo model systems, collectively suggesting the potential of IgE immunotherapies in oncology. Translation toward clinical application is now in progress.",
keywords = "Animals, Antibodies, Neoplasm/immunology, Antineoplastic Agents, Humans, Immunization, Passive, Immunoglobulin E/immunology, Immunologic Surveillance/drug effects, Neoplasms, Experimental/drug therapy",
author = "Josephs, {Debra H} and Spicer, {James F} and Panagiotis Karagiannis and Gould, {Hannah J} and Karagiannis, {Sophia N}",
year = "2014",
month = jan,
day = "16",
doi = "10.4161/mabs.27029",
language = "English",
volume = "6",
pages = "54--72",
journal = "MABS-AUSTIN",
issn = "1942-0862",
publisher = "LANDES BIOSCIENCE",
number = "1",

}

RIS

TY - JOUR

T1 - IgE immunotherapy: a novel concept with promise for the treatment of cancer

AU - Josephs, Debra H

AU - Spicer, James F

AU - Karagiannis, Panagiotis

AU - Gould, Hannah J

AU - Karagiannis, Sophia N

PY - 2014/1/16

Y1 - 2014/1/16

N2 - The importance of antibodies in activating immune responses against tumors is now better appreciated with the emergence of checkpoint blockade antibodies and with engineered antibody Fc domains featuring enhanced capacity to focus potent effector cells against cancer cells. Antibodies designed with Fc regions of the IgE class can confer natural, potent, long-lived immune surveillance in tissues through tenacious engagement of high-affinity cognate Fc receptors on distinct, often tumor-resident immune effector cells, and through ability to activate these cells under tumor-induced Th2-biased conditions. Here, we review the properties that make IgE a contributor to the allergic response and a critical player in the protection against parasites, which also support IgE as a novel anti-cancer modality. We discuss IgE-based active and passive immunotherapeutic approaches in disparate in vitro and in vivo model systems, collectively suggesting the potential of IgE immunotherapies in oncology. Translation toward clinical application is now in progress.

AB - The importance of antibodies in activating immune responses against tumors is now better appreciated with the emergence of checkpoint blockade antibodies and with engineered antibody Fc domains featuring enhanced capacity to focus potent effector cells against cancer cells. Antibodies designed with Fc regions of the IgE class can confer natural, potent, long-lived immune surveillance in tissues through tenacious engagement of high-affinity cognate Fc receptors on distinct, often tumor-resident immune effector cells, and through ability to activate these cells under tumor-induced Th2-biased conditions. Here, we review the properties that make IgE a contributor to the allergic response and a critical player in the protection against parasites, which also support IgE as a novel anti-cancer modality. We discuss IgE-based active and passive immunotherapeutic approaches in disparate in vitro and in vivo model systems, collectively suggesting the potential of IgE immunotherapies in oncology. Translation toward clinical application is now in progress.

KW - Animals

KW - Antibodies, Neoplasm/immunology

KW - Antineoplastic Agents

KW - Humans

KW - Immunization, Passive

KW - Immunoglobulin E/immunology

KW - Immunologic Surveillance/drug effects

KW - Neoplasms, Experimental/drug therapy

U2 - 10.4161/mabs.27029

DO - 10.4161/mabs.27029

M3 - SCORING: Review article

C2 - 24423620

VL - 6

SP - 54

EP - 72

JO - MABS-AUSTIN

JF - MABS-AUSTIN

SN - 1942-0862

IS - 1

ER -